Jonathan L. Doty

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 331 citations · Full text

Immunology, Janus Tyrosine Kinases, Immunotherapy +19

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives

Rodney C. Schnur, Michael L. Corman, Randall J. Gallaschun et al. · Journal of Medicinal Chemistry · 1995 · 199 citations

erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships

Rodney C. Schnur, Michael L. Corman, Randall J. Gallaschun et al. · Journal of Medicinal Chemistry · 1995 · 138 citations

Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections

Justin I. Montgomery, Matthew F. Brown, Usa Reilly et al. · Journal of Medicinal Chemistry · 2012 · 97 citations · Full text

Pharmaceutical Science, Pharmacotherapy, New Series +19

Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections

Matthew F. Brown, Usa Reilly, J. A. Abramite et al. · Journal of Medicinal Chemistry · 2011 · 97 citations · Full text